GLPG - Galapagos NV Sales Growth YoY (TTM)

Galapagos NV aims to become a leader in oncology and immunology through the implementation of accessible CAR-T therapy. The current sales growth rate over a rolling 12-month period year-over-year confirms this trend, with the latest value recorded as 332.90. Prospects are based on heavy R&D investments in cell therapy, although the risk of expiring patents makes the approval of new drugs in the US and EU critical.
glpg.com (GLPG) - metric breakdowns and financial figures

For biopharmaceutical leader Galapagos NV (GLPG), revenue dynamics reflect the commercialization efficiency of cell technologies and small molecules. This metric measures the percentage change in total revenue over the last 12 months relative to the same period last year. By analyzing this rolling 12-month YoY revenue growth chart, investors can assess the business's resilience to market pressure. A steady upward trend confirms the successful monetization of R&D investments and long-term potential for market share expansion.